{
  "Cancer Histology Subtype (At)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20171128_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        1103, 
        1109
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        1165, 
        1171
      ]
    }
  ], 
  "Cancer Histology Type (Ov)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20171128_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        1075, 
        1084
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        1172, 
        1181
      ]
    }
  ], 
  "Clinical History Heading (At)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20171128_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        896, 
        919
      ]
    }
  ], 
  "Comments Heading (At)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20171128_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        2799, 
        2819
      ]
    }
  ], 
  "Final Diagnosis Heading (At)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20171128_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        983, 
        1010
      ]
    }
  ], 
  "Laterality (Ov)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20171128_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        1012, 
        1017
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20171128_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        2623, 
        2628
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20171128_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        2699, 
        2704
      ]
    }
  ], 
  "Macroscopic/Gross Description Heading (At)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20171128_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        566, 
        595
      ]
    }
  ], 
  "Microscopic Heading (At)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20171128_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        2435, 
        2470
      ]
    }
  ], 
  "Nature of Specimen Heading (At)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20171128_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        2511, 
        2537
      ]
    }
  ], 
  "Neoplasm Behaviour (Ov)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20171128_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        1058, 
        1066
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        1182, 
        1189
      ]
    }
  ], 
  "Neoplasm Grade Value (At)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20171128_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        1147, 
        1148
      ]
    }
  ], 
  "Organ/Body Structure (At)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20171128_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        1018, 
        1024
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20171128_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        1067, 
        1074
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20171128_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        2629, 
        2635
      ]
    }
  ], 
  "Relative Distance (Ov)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20171128_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        2555, 
        2562
      ]
    }
  ], 
  "Relative Location (Ov)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Steven,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        1031, 
        1041
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Steven,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        2542, 
        2552
      ]
    }
  ], 
  "Specimen Identifier (At)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        2539, 
        2540
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        2696, 
        2698
      ]
    }
  ], 
  "Supplementary Report Heading (At)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20171128_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        1260, 
        1292
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20171128_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        1294, 
        1309
      ]
    }
  ], 
  "__text": "MSH|^~\\&|PathSys|Associated Pathologists, LLC d/b/a PathGroup^44D0934312^CLIA|eMARCPlus|TN Cancer Registry|20170919125820||ORU^R01^ORU_R01|201709191258200001|P|2.5.1|TN||||||||VOL_V_40_ORU_R01-CCR1^NAACCR_CP\nOBR|1||17-11-037778^PathSys^44D0934312^CLIA|11529-5^SURGICAL PATH REPORT^LN|||20170824000000|||||||20170825000000|&Breast, Stereotactic biopsy|1376690263^^^^^^MD^^CMS^D^^^NPI||||||20170825000000|||F||||||C50.411^Malignant neoplasm of upper-outer quadrant of right female breast^I10~D05.11^Intraductal carcinoma in situ of right breast^I10|&&&&&&&&CMS\n\n\n\n\n\n\n\nPath report.gross description\n\nThe specimen is received in a container of formalin labeled \", right breast\" and consists of multiple yellow-tan core biopsies and core fragments measuring from 0.1 to 1.5 cm in length and up to 0.2 cm in diameter. The specimens are submitted entirely in cassettes 1A-1C. 1A-1B, 4/1 each; 1C, M/1\n\n\nPath report.relevant Hx\n\nHistory - Right breast mass, right axillary lymphadenopathy\n\n\nPath report.final diagnosis\n\nRight breast mass, 10-o'clock, core biopsy:   Invasive mammary carcinoma, no special type (ductal, not otherwise specified),     grade 3. See comment.   Ductal carcinoma in situ, high grade, comedo type.   Lymphovascular invasion not identified.\n\n\nPath report.supplemental reports\n\nAddendum Report: Dr. 's office notified of diagnosis (Marilyn), 8/28/17, 8:40 CST ## End of auxiliary report ## Hormone Receptor report: Paraffin immunoperoxidase stained slides are examined using antibodies to nuclear estrogen receptor, nuclear progesterone receptor and HER-2. The internal and external control slides stain appropriately. The tumor is negative for nuclear estrogen receptor. There is 1+ nuclear positivity in approximately 5% of the cells for progesterone receptor which is considered a positive result. There is no immunohistochemical evidence of HER-2 overexpression. Impression: Right breast mass, 10-o'clock, core biopsy:   NEOPLASTIC CELLS ARE NEGATIVE FOR NUCLEAR ESTROGEN RECEPTOR.   NEOPLASTIC CELLS ARE WEAKLY POSITIVE FOR NUCLEAR PROGESTERONE RECEPTOR.   NEOPLASTIC CELLS SHOW NO IMMUNOHISTOCHEMICAL EVIDENCE OF HER-2 OVEREXPRESSION.   Confirmatory HER-2 FISH studies will be performed and reported separately.  ## End of auxiliary report ## Fish Report: FISH - NEGATIVE for HER2 oncogene amplification by FISH analysis  NEGATIVE for chromosome 17 polysomy by FISH analysis       ## End of auxiliary report ##\n\n\nPath report.microscopic examination\n\nMicroscopic evaluation is performed.\n\n\nPath report.site of origin\n\n1. 10 o'clock , 6 cm FN, center hyperechoic heterogenous, vascular irregular shaped right breast mass with punctate echogenic foci measuring 52 x 25 x 39 mm 2. Right axillary lymphadenopathy measuring 25 x 21 x 16 mm with a thickening cortex and fatty hilum\n\n\nPath report.comments\n\nComments - Invasive tumor is seen in all submitted cores (greater than 80% total biopsy tissue). Tumor grade was determined by evaluating the following criteria: Tubules, 3; mitoses, 2; nuclear pleomorphism, 3. Hormone receptor studies will be requested. The results will follow as an addendum at a later date. FISH Comments - The HER2 FISH assay (Abbott Molecular/Vysis, Inc.) did not reveal amplification of the HER2 oncogene. A ratio of HER-2 gene signals to the centromeric control probe of chromosome 17 (CEP 17) signals was 1.02 and a Her2 copy number of 2.08, (ratio less than 2.0 and Her2 copy number <4), indicating absence of amplification. There was no evidence of polysomy/polyploidy or genetic heterogeneity. Clinical correlation is recommended.    A ratio less than 2.0 and Her2 copy number less than 4 indicates absence of amplification.  A ratio less than 2.0 and Her2 copy number greater or equal to 4 and less than 6 indicates an equivocal value and per ASCO/CAP guidelines, requires reflex to another (IHC for Her2) test.  A ratio greater than or equal to 2.0 or average Her2 copy number greater or equal to 6 indicates gene amplification.    Regions of invasive tumor were defined by a pathologist. The tumor was fixed in formalin (recommended 6-72hrs). Tumor fixed outside the recommended fixation time should be interpreted with caution. Controls were performed and provided the anticipated results. This case has been reviewed by at least 2 observers.\n\n\n"
}